Adipose tissue has gained significant attention for its role in immune response and inflammation through the secretion of adipokines. Adipokines, such as leptin and adiponectin, are secreted by adipose tissue and have been implicated in various physiological processes, with a focus on their role in modulating immune responses and inflammation. Leptin and adiponectin are the most abundant adipokines in human, playing a crucial role in regulating functions of the heart, skeletal muscle, growth, and inflammation. Leptin, a pro-inflammatory adipokine, is involved in controlling food intake and energy expenditure, and it influences immune cell activation and cytokine production. In contrast, adiponectin, an anti-inflammatory adipokine, circulates at high levels in the plasma and modulates immune cell functions, counteracting the effects of leptin. Here we provided an overview of the role of adipokines in immune response and inflammation. In addition,The leptin-adiponectin ratio (Adpn/Lep) has emerged as a significant indicator of various metabolic diseases and conditions. Further research is needed to fully elucidate the mechanisms by which adipokines influence immune responses and to identify potential therapeutic targets for inflammatory and metabolic disorders.
Hepatocellular carcinoma (HCC) represents the most prevalent form of liver cancer. Despite notable advancements in therapeutic strategies, HCC continues to pose significant public health challenges due to its rising incidence and high mortality rates worldwide. Selenium is an essential trace element that playing a critical role in human health. Recent studies have highlighted its potential preventive and therapeutic benefits in the context of HCC. However, some in vitro and in vivo investigations have yielded inconsistent results, and the mechanisms by which selenium influences HCC are still not completely clear. This review begins by providing an extensive evaluation of the effects and mechanisms of selenium on the primary risk factors associated with HCC, including viral infections, metabolic abnormalities, and lifestyle factors. Subsequently, we outline the roles and mechanisms by which selenium influences the proliferation, metastasis, and immune microenvironment of HCC. Finally, we emphasize the imperative for further investigation into the optimal dosage and forms of selenium, as well as its effects on the HCC microenvironment, to inform the development of effective clinical strategies. This review thus provides a foundational framework for the potential clinical application of selenium in the treatment of HCC.
1 February 2026 in International Journal of Nanomedicine
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. Research indicates that inflammatory responses and oxidative stress mediated by reactive oxygen species (ROS) are hallmark pathological mechanisms of CVD. Traditional anti-inflammatory drugs, though widely used, have limitations such as lack of targeting, low systemic delivery efficiency, and significant side effects. Nanozymes are a class of nanomaterials with enzyme-like activity, and their breakthrough applications offer new directions for the prevention and treatment of CVD. In the treatment of cardiovascular diseases, nanozymes demonstrate unique advantages: they can achieve local targeted delivery and ROS scavenging, and can also regulate the inflammatory microenvironment through multi-mechanism interventions. However, despite their promising applications, nanozymes still face challenges such as optimizing catalytic selectivity, improving biological targeting efficiency, and verifying long-term safety. This article will review the mechanisms of action of nanozymes in inflammation regulation and summarize their applications in cardiovascular diseases.
Cancer cachexia (CC) is a prevalent metabolic disorder in patients with advanced cancer, characterized by persistent skeletal muscle mass loss and irreversible body weight reduction, which significantly diminishes quality of living, therapeutic effectiveness. At present, the specific pathogenesis of CC is only defined as skeletal muscle loss induced by signaling pathways. In the clinical treatment of tumor cachexia, it has been clearly defined that there are multiple methods available for treating this disease, including nutritional therapy and exercise, but all of them have very little therapeutic effect. Surprisingly, traditional Chinese medicine has achieved initial success in treating malignant tumors, and the combined treatment of traditional Chinese and Western medicine has yielded remarkable results. Therefore, it is an urgent need to elucidate the more specific pathogenesis of CC to develop effective treatment approaches, which enhance patients’ nutritional health status as well as their overall quality of life and survival ratings. This article aims to review the pathogenesis of CC along with clinical treatment strategies and drug utilization.
6 September 2026 in European Journal of Cell Biology
De novo lipogenesis (DNL) operates as a core metabolic pathway in cellular lipid homeostasis, yet its central effector enzyme fatty acid synthase (FASN) undergoes aberrant overexpression and hyperactivation in tumors and metabolic disorders. Herein, we systematically outline the versatile functions of FASN in tumor lipogenic metabolism and summarize recent advances in its covalent regulatory modifications. We highlight nucleic acids methylation modifications, acetylation, ubiquitination, glycosylation, ubiquitin-like modification, palmitoylation and phosphorylation modifications as an integrated network that tune FASN stability, catalytic activity, and subcellular localization. These modifications exhibit extensive crosstalk and disease-specific heterogeneity, offering potential molecular targets for therapeutic intervention in cancer and metabolic diseases.
1 December 2025 in International Immunopharmacology